Study on Ravulizumab for Children Aged 6 to 17 with Generalized Myasthenia Gravis
- Substances:Ravulizumab
France- Participants:0–17 years · 18–64 years
- Substances:Ravulizumab
- Sponsor:Alexion Pharmaceuticals Inc.
Rare diseases
Investigational molecules
Locations
328 conditions with trials, the busiest first
865 trials across Europe, recruiting first
FranceStudy on Nipocalimab for Children Aged 2-17 with Generalized Myasthenia Gravis
The NetherlandsStudy on Treating Adynamic Bone Disorder with Teriparatide in Patients with Chronic Kidney Disease
DenmarkStudy on the Use of Romosozumab and Zoledronic Acid for Treating Osteoporosis in Patients
DenmarkStudy on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis
BelgiumStudy on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma
CyprusStudy of Personalized Peptide Vaccine with PERVI-FUS, PERVI-NEO, and 11902A for Children and Young Adults with Metastatic Fusion-Driven Sarcomas
GermanyStudy on the Safety and Body Processing of Bimekizumab in Children with Juvenile Idiopathic Arthritis
FranceStudy on the Effects of Ferric Derisomaltose and Dopaminergic Therapy for Patients with Restless Legs Syndrome
AustriaStudy of Pembrolizumab and Cabozantinib for Patients with Advanced Sarcomas: Undifferentiated Pleomorphic Sarcoma, Osteosarcoma, and Ewing Sarcoma
FranceStudy on the Safety and Efficacy of Avalglucosidase Alfa for Patients Aged 5 and Older with Non-Classic Pompe Disease
The NetherlandsStudy Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients
FranceThe therapies tested most often in Musculoskeletal and connective tissue disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.